Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × OTHER × Pseudomyxoma Peritonei × Clear all

Phase

Phase 2 7 Phase NA 4 Phase 1 2 Phase EARLY_PHASE1 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 148 Neoplasms 80 Prostatic Neoplasms 79 Glioblastoma 67 Pancreatic Neoplasms 60 Multiple Myeloma 59 Glioma 57 Brain Neoplasms 50 Lung Neoplasms 41 Head and Neck Neoplasms 41 Leukemia, Myeloid, Acute 39 Carcinoma, Hepatocellular 39 Melanoma 37 Recurrence 35 Colorectal Neoplasms 33 Carcinoma, Non-Small-Cell Lung 33 Ovarian Neoplasms 32 Squamous Cell Carcinoma of Head and Neck 31 Polycystic Ovary Syndrome 26 Neoplasm Metastasis 26 Precursor Cell Lymphoblastic Leukemia-Lymphoma 25 Lymphoma 24 Carcinoma, Renal Cell 24 Lymphoma, Non-Hodgkin 23 Hematologic Neoplasms 22 Stomach Neoplasms 21 Urinary Bladder Neoplasms 18 Triple Negative Breast Neoplasms 18 Sarcoma 18 Lymphoma, Large B-Cell, Diffuse 18

Interventions

tislelizumab 1 molgramostim 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07341360 2026-01-14

Pseudovax

Oslo University Hospital

Phase EARLY_PHASE1 Recruiting

Pseudomyxoma Peritonei

Data powered by HemOnc (CC BY 4.0) Colophon ⚡